Xanthine
|
Basic information |
| Metabolite name | Xanthine |
 | HMDB0000292 |
 |
C00385 |
 |
1188 |
| Synonyms | 2,6-Dihydroxypurine |
| No. of studies | 30 |
|
Basic information |
| Metabolite name | Xanthine |
| HMDB0000292 |
|
C00385 |
|
1188 |
| Synonyms | 2,6-Dihydroxypurine |
| No. of studies | 30 |
|
Relationship between Xanthine and depression (count: 30) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M011 | Type4 | placebo-treated responder group vs. non-responder group | Serum | Human | Unknown |
| Study M037 | Type2 | sertraline treatment group four-week vs. baseline | Serum | Human | Down |
| Study M037 | Type2 | placebo treatment group one-week vs. baseline | Serum | Human | Down |
| Study M073 | Type1 | depressed group vs. control group | Serum | Human | Up |
| Study M089 | Type3 | fluoxetine vs. control group | Plasma | Rhesus monkey | Up |
| Study M1066 | Type1 | CUMS group vs. control group | Kidney | Sprague-Dawley rat | Down |
| Study M1066 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Kidney | Sprague-Dawley rat | Up |
| Study M1072 | Type1 | CUMS group vs. control group | Intestine | Cynomolgus monkey | Up |
| Study M1093 | Type1 | CSDS group vs. control group | Serum | C57BL/6N mouse | Up |
| Study M1098 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1098 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1098 | Type2 | CUMS + L-theanine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1099 | Type3 | fluoxetine group vs. control group | Prefrontal cortex | Wistar rat | Down |
| Study M208 | Type1 | GCI model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M454 | Type1 | vascular depression model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M454 | Type2 | vascular depression model + YXST group vs. vascular depression model group | Hippocampus | ICR mouse | Up |
| Study M460 | Type1 | depressed group vs. control group | Liver | Kunming mouse | Up |
| Study M539 | Type1 | LPS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M540 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M613 | Type1 | CSDS susceptible group vs. control group | Serum | C57BL/6 J mouse | Down |
| Study M630 | Type2 | acupuncture + antidepressant group, post vs. before treatment | Urine | Human | Up |
| Study M689 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M769 | Type1 | CSDS group vs. control group | Amygdala | Sprague-Dawley rat | Down |
| Study M772 | Type1 | CUMS group vs. control group | Amygdala | Sprague-Dawley rat | Down |
| Study M814 | Type1 | CSDS group vs. control group | Serum | C57BL/6J mouse | Down |
| Study M828 | Type2 | ultrasonic radiation + intraperitoneally clomipramine group vs. ultrasonic radiation group | Hippocampus | Wistar rat | Up |
| Study M847 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M867 | Type2 | CUMS + Baihe-Dihuang Tang group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M883 | Type1 | MDD group vs. control group | Blood | Human | Up |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Cerebrospinal fluid | Human | Up |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Plasma | Human | Down |
| Study M940 | Type1 | CUMS group vs. control group | Cerebral cortex | Sprague-Dawley rat | Up |
| Study M940 | Type2 | CUMS + Chaihu group vs. CUMS group | Cerebral cortex | Sprague-Dawley rat | Down |
| Study M940 | Type2 | CUMS + Chaihu-Baishao herb pair group vs. CUMS group | Cerebral cortex | Sprague-Dawley rat | Down |
| Study M953 | Type2 | CRS + Shugan Granule group vs. CRS group | Faece | Sprague-Dawley rat | Up |
| Study M955 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6J mouse | Down |
| Study M956 | Type1 | CUMS group vs. control group | Faece | C57BL/6J mouse | Up |
| Study M956 | Type2 | CUMS + whey protein-based group vs. CUMS group | Faece | C57BL/6J mouse | Down |
| Study M956 | Type2 | CUMS + deoiled sunflower seeds group vs. CUMS group | Faece | C57BL/6J mouse | Down |
| Study M957 | Type1 | CSDS group vs. control group | Hippocampus | C57BL/6 J mouse | Up |
| Study M957 | Type1 | CSDS group vs. control group | Serum | C57BL/6 J mouse | Up |